Vitale Nancy 4

What Happened
Nancy Vitale, a director of Voyager Therapeutics, was granted a stock option award to acquire 30,000 shares on June 9, 2026. The Form 4 reports the derivative acquisition at $0.00 (reported value $0); the filing characterizes this as an award under the company's 2025 Stock Incentive Plan and director compensation policy. This is a grant (award) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; filing date: 2026-06-11 (timely — Form 4 filed within 2 days).
• Reported transaction: Grant/award of a derivative (stock option) for 30,000 shares; price shown as $0.00 and total $0 in the filing summary provided.
• Shares owned after transaction: Not specified in the summary provided.
• Footnote: The option vests upon the earlier of the one-year anniversary of the grant date (vesting commencement date) or the next annual meeting of stockholders, conditioned on continued service as a director. The award was made under the 2025 Stock Incentive Plan per the director compensation policy.
• Exhibit noted: Exhibit 24 — Power of Attorney.

Context
This was an award of options to a non-employee director as part of routine director compensation. It is not an exercise or sale, and the filing does not indicate any immediate sale or cashless exercise of shares. The Form 4 summary provided does not disclose the option's exercise price or the grant’s fair value; those details may appear in other company disclosures (e.g., proxy or 10-Q/10-K). Awards to directors are common and typically reflect compensation rather than a direct market signal.